Evolving Role of CRS and HIPEC: Current Indications

Chapter

Abstract

Peritoneal surface oncology is a dynamic field. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as an aggressive locoregional therapy that can prolong the life of selected patients with peritoneal metastases (PM). Initially, all sites of origin of PM were dealt with using the same prognostic variables, and the results were evaluated using the same parameters. Currently, PM secondary to various primary tumors or arising de novo from the peritoneum are dealt with individually with different indications, timing of CRS and HIPEC, and integration with other therapies. The indications may be considered fairly standardized. Though majority of these are supported by level 3 evidence that comprises of retrospective case series, these studies offer the most practical design for a situation where two radically different treatments (CRS and HIPEC versus systemic chemotherapy) need to be compared. Ongoing phase III trials in the therapeutic setting have been designed to compare CRS alone with CRS and HIPEC with or without other systemic therapies in various clinical scenarios. Like the role of surgery for nonmetastatic disease which has been established not by randomized controlled trials but through comparison with historical controls in most cancers, the role of CRS as a potentially curative treatment for selected patients with PM can be established based on the significant gain in survival over palliative therapies. It is the added benefit of HIPEC that is undefined in most conditions.

A significant proportion of patients treated with a curative intent develop recurrence, and reiterative CRS and HIPEC is being performed in selected patients with a good long-term survival and an acceptable morbidity. Another area of current research is the prevention of peritoneal spread in patients considered at risk for developing it, and the role of HIPEC in the prevention of PM is being evaluated in randomized controlled trials. The results of these trials my further expand the role of HIPEC. The introduction of newer therapies like pressurized intraperitoneal aerosol chemotherapy (PIPAC) that are also being evaluated in clinical trials could further modify the timing and indications for CRS and HIPEC.

Keywords

Cytoreductive surgery HIPEC Indications Evidence-based indications Clinical trials 

References

  1. 1.
    Thomassen I, van Gestel YR, Lemmens VE, de Hingh IH. Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin. Dis Colon Rectum. 2013;56(12):1373–80.  https://doi.org/10.1097/DCR.0b013e3182a62d9d.CrossRefPubMedGoogle Scholar
  2. 2.
    Neuwirth MG, Alexander HR, Karakousis GC. Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective. J Gastrointest Oncol. 2016;7(1):18–28.  https://doi.org/10.3978/j.issn.2078-6891.2015.106.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Bartlett DL. HIPEC: the complexities of clinical trials. Ann Surg Oncol. 2008;15(5):1277–9.  https://doi.org/10.1245/s10434-007-9768-y.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Meigs JV. Tumors of the female pelvic organs. New York: Macmillan; 1934.Google Scholar
  5. 5.
    Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29–42.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Gilly FN, Beaujard A, Glehen O, et al. Peritonectomy combined with intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: phase I-II study. Anticancer Res. 1999;19:2317–21.PubMedGoogle Scholar
  7. 7.
    Glehen O, Cotte E, Kusamura S, et al. Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. J Surg Oncol. 2008;98:242–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Elias D, Antoun S, Goharin A, et al. Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. Int J Surg Investig. 2000;1:431–9.PubMedGoogle Scholar
  9. 9.
    Ceelen W, Flessner M. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol. 2009;2010(7):108–15.  https://doi.org/10.1038/nrclinonc.2009.217.Google Scholar
  10. 10.
    Brucher BL, Piso P, Verwaal V, Esquivel J, Derraco M, Yonemura Y, Gonzalez-Moreno S, Pelz J, Konigsrainer A, Strohlein M, Levine EA, Morris D, Bartlett D, Glehen O, Garofalo A, Nissan A. Peritoneal carcinomatosis: cytoreductive surgery and HIPEC—overview and basics. Cancer Investig. 2012;30:209–24.CrossRefGoogle Scholar
  11. 11.
    Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol. 2002;43:33–56.CrossRefPubMedGoogle Scholar
  12. 12.
    Mohamed F, Cecil T, Moran B, Sugarbaker P. A new standard of care for the management of peritoneal surface malignancy. Curr Oncol. 2011;18(2):e84–96.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Goéré D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg. 2013;257:1065–71.  https://doi.org/10.1097/SLA.0b013e31827e9289.CrossRefPubMedGoogle Scholar
  14. 14.
    Chia CS, You B, Decullier E, et al. Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? Ann Surg Oncol. 2016;23:1971.  https://doi.org/10.1245/s10434-015-5081-3.CrossRefPubMedGoogle Scholar
  15. 15.
    Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.CrossRefPubMedGoogle Scholar
  16. 16.
    Smeenk RM, Verwaal VJ, Zoetmulder FA. Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg. 2007;94:1408–14.CrossRefPubMedGoogle Scholar
  17. 17.
    Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg. 2009;249:900–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Dreyer NA, Garner S. Registries for robust evidence. JAMA. 2009;302(7):790–1.CrossRefPubMedGoogle Scholar
  19. 19.
    Reymond M. The quest of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): searching for evidence. Pleura Peritoneum. 2016;1(4):167–8.CrossRefGoogle Scholar
  20. 20.
    Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43.CrossRefPubMedGoogle Scholar
  21. 21.
    Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal metastasis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575–81.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal metastasis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014;110:275–84.CrossRefPubMedGoogle Scholar
  23. 23.
    Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, Giassas S. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22:1570–5.CrossRefPubMedGoogle Scholar
  24. 24.
    PDQ® Adult Treatment Editorial Board. PDQ levels of evidence for adult and pediatric cancer treatment studies. Bethesda: National Cancer Institute. Updated <05/19/2017>. Available at: https://www.cancer.gov/publications/pdq/levels-evidence/treatment. Accessed <07/01/2017>. [PMID: 26389191].
  25. 25.
    Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol. 1995;19(12):1390.CrossRefPubMedGoogle Scholar
  26. 26.
    Moran B, Baratti D, Yan TD, Kusamura S, Deraco M. Consensus statement on the locoregional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol. 2008;98(4):277–82.  https://doi.org/10.1002/jso.21054.CrossRefPubMedGoogle Scholar
  27. 27.
    Yan TD, Black D, Savady R, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2007;14(2):484–92. Epub 200.CrossRefPubMedGoogle Scholar
  28. 28.
    Gough DB, Donohue JH, Schutt AJ, Gonchoroff N, Goellner JR, Wilson TO, Naessens JM, O’Brien PC, van Heerden JA. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg. 1994;219:112–9.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Nitecki SS, Wolff BG, Schlinkert R, et al. The natural history of surgically treated primary adeno- carcinoma of the appendix. Ann Surg. 1994;219:51–7.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6:727–31.CrossRefPubMedGoogle Scholar
  31. 31.
    Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, González-Moreno S, Van Der Speeten K, Morris DL. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–56.CrossRefPubMedGoogle Scholar
  32. 32.
    Ansari N, Chandrakumaran K, Dayal S, Mohamed F, Cecil TD, Moran BJ. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours. Eur J Surg Oncol. 2016;42(7):1035–41.  https://doi.org/10.1016/j.ejso.2016.03.017.CrossRefPubMedGoogle Scholar
  33. 33.
    Lord AC, Shihab O, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours. Eur J Surg Oncol. 2015;41(3):396–9.  https://doi.org/10.1016/j.ejso.2014.08.476.CrossRefPubMedGoogle Scholar
  34. 34.
    Yan TD, Bijelic L, Sugarbaker PH. Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms. Ann Surg Oncol. 2007;14(8):2289–99.CrossRefPubMedGoogle Scholar
  35. 35.
    Delhorme JB, Honoré C, Benhaim L, Dumont F, Dartigues P, Dromain C, Ducreux M, Elias D, Goéré D. Long-term survival after aggressive treatment of relapsed serosal or distant pseudomyxoma peritonei. Eur J Surg Oncol. 2017;43(1):159–67.  https://doi.org/10.1016/j.ejso.2016.08.021.CrossRefPubMedGoogle Scholar
  36. 36.
    Golse N, Bakrin N, Passot G, Mohamed F, Vaudoyer D, Gilly FN, Glehen O, Cotte E. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results. J Surg Oncol. 2012;106(2):197–203.  https://doi.org/10.1002/jso.23062.CrossRefPubMedGoogle Scholar
  37. 37.
    Mohamed F, Chang D, Sugarbaker PH. Third look surgery and beyond for appendiceal malignancy with peritoneal dissemination. J Surg Oncol. 2003;83:5–12.CrossRefPubMedGoogle Scholar
  38. 38.
    Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32.CrossRefPubMedGoogle Scholar
  39. 39.
    Esquivel J. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: survival outcomes and patient selection. J Gastrointest Oncol. 2016;7(1):72–8.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–5.  https://doi.org/10.1200/JCO.2008.19.7160.CrossRefPubMedGoogle Scholar
  41. 41.
    Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.  https://doi.org/10.1200/JCO.2009.23.9285.CrossRefPubMedGoogle Scholar
  42. 42.
    Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263–7.CrossRefPubMedGoogle Scholar
  43. 43.
    Klaver YL, Simkens LH, Lemmens VE, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38:617–23.CrossRefPubMedGoogle Scholar
  44. 44.
    Goéré D, Souadka A, Faron M, et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol. 2015;22:2958–64.  https://doi.org/10.1245/s10434-015-4387-5.CrossRefPubMedGoogle Scholar
  45. 45.
    Sammartino P, Sibio S, Biacchi D, et al. Prevention of peritoneal metastases from colon cancer in high-risk patients: preliminary results of surgery plus prophylactic HIPEC. Gastroenterol Res Pract. 2012;2012:141585.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Ihemelandu C, Sugarbaker PH. Management for peritoneal metastasis of colonic origin: role of cytoreductive surgery and perioperative intraperitoneal chemotherapy: a single institution’s experience during two decades. Ann Surg Oncol. 2017;24:898–905.  https://doi.org/10.1245/s10434-016-5698-x.CrossRefPubMedGoogle Scholar
  47. 47.
    Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92.CrossRefPubMedGoogle Scholar
  48. 48.
    Passot G, You B, Boschetti G, Fontaine J, Isaac S, Decullier E, Maurice C, Vaudoyer D, Gilly FN, Cotte E, Glehen O. Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Ann Surg Oncol. 2014;21:2608–14.CrossRefPubMedGoogle Scholar
  49. 49.
    Verwaal VJ, Boot H, Aleman BM, et al. Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome. Ann Surg Oncol. 2004;11:375–9.CrossRefPubMedGoogle Scholar
  50. 50.
    Bijelic L, Yan TD, Sugarbaker PH. Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol. 2007;14:2281–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Saxena A, Yan TD, Morris DL. Critical assessment of preoperative and operative risk factors for complications after iterative peritonectomy procedures. Eur J Surg Oncol. 2010;36:309–14.CrossRefPubMedGoogle Scholar
  52. 52.
    Cashin PH, Graf W, Nygren P, Mahteme H. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study. Eur J Surg Oncol. 2012;38(6):509–15.CrossRefPubMedGoogle Scholar
  53. 53.
    Alzharani N, Huang Y, Baratti D, Deraco M, et al. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer in 189 patients (PSOGI collaboration). J Peritoneum. 2016;1(1):1.Google Scholar
  54. 54.
    Chan DL, Morris DL, Rao A, Chua TC. Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. Cancer Manag Res. 2012;4:413–22.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;11:CD005340.Google Scholar
  56. 56.
    Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43.CrossRefPubMedGoogle Scholar
  57. 57.
    NCI Clinical Announcement on Intraperitoneal Chemotherapy in Ovarian Cancer (January 5, 2006) https://ctep.cancer.gov/highlights/20060105_ovarian.htm.
  58. 58.
    Hettinga JV, Konings AW, Kampinga HH. Reduction of cellular cisplatin resistance by hyperthermia—a review. Int J Hyperth. 1997;13:439–57.CrossRefGoogle Scholar
  59. 59.
    van de Vaart PJ, van der Vange N, Zoetmulder FA, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW, Beijnen JH, Bartelink H, Begg AC. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer. 1998;34(1):148–54.CrossRefPubMedGoogle Scholar
  60. 60.
    Mulier S, Claes JP, Dierieck V, Amiel JO, Pahaut JP, Marcelis L, Bastin F. Survival benefit of adding hyperthermic IntraPEritoneal chemotherapy (HIPEC) at the different time- points of treatment of ovarian cancer: review of evidence. Curr Pharm Des. 2012;18:3793–803.CrossRefPubMedGoogle Scholar
  61. 61.
    Parson EN, Lentz S, Russell G, et al. Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms. Am J Surg. 2011;202(4):481–6.CrossRefPubMedGoogle Scholar
  62. 62.
    Gonzalez Bayon L, Steiner MA, Vasquez Jimenez W, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemo- therapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later? Eur J Surg Oncol. 2013;39:1109–15.CrossRefPubMedGoogle Scholar
  63. 63.
    Helm CW, Richard SD, Pan J, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER- O registry. Int J Gynecol Cancer. 2010;20(1):61–9.CrossRefPubMedGoogle Scholar
  64. 64.
    Deraco M, Kusamura S, Virzì S, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol. 2011;122(2):215–20.CrossRefPubMedGoogle Scholar
  65. 65.
    Bakrin N, Bereder JM, Decullier E, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of566 patients. Eur J Surg Oncol. 2013;39:1435–43.CrossRefPubMedGoogle Scholar
  66. 66.
    Fagotti A. Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis. Gynecol Oncol. 2014;134(2):257–61. https://doi.org/10.1016/j.ygyno.2014.05.029. Epub 2014 Jun 5.CrossRefPubMedGoogle Scholar
  67. 67.
    Carrabin N, Mithieux F, Meeus P, et al. Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer. Bull Cancer. 2010;97(4):E23–32.PubMedGoogle Scholar
  68. 68.
    Königsrainer I, Beckert S, Becker S, et al. Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: experience and lessons learned. Langenbeck’s Arch Surg. 2011;396(7):1077–81.CrossRefGoogle Scholar
  69. 69.
    Coccolini F, Campanati L, Catena F, Ceni V, Ceresoli M, Jimenez Cruz J, Lotti M, Magnone S, Napoli J, Rossetti D, De Iaco P, Frigerio L, Pinna A, Runnebaum I, Ansaloni L. Hyperthermic intra- peritoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study. J Gynecol Oncol. 2015;1:54–61.  https://doi.org/10.3802/jgo.2015.26.1.5467.
  70. 70.
    Munoz-Casares FC, Rufian S, Rubio MJ, et al. The role of hyper-thermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin Transl Oncol. 2009;11:753–759 68.CrossRefPubMedGoogle Scholar
  71. 71.
    Spiliotis J, Vaxevanidou A, Sergouniotis F, Lambropoulou E, Datsis A, Christopoulou A. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study. J BUON. 2011;16:74–9.PubMedGoogle Scholar
  72. 72.
    Safra T, Grisaru D, Inbar M, Abu-Abeid S, Dayan D, Matceyevsky D, Weizman A, Klausner JM. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA- positive patients- a case-control study. J Surg Oncol. 2014;110(6):661–5.  https://doi.org/10.1002/jso.23688.CrossRefPubMedGoogle Scholar
  73. 73.
    Cascales-Campos PA, Gil J, Feliciangeli E, Gil E, González-Gil A, López V, Ruiz-Pardo J, Nieto A, Parrilla JJ. Parrilla the role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction. Ann Surg Oncol. 2015;22(3):987–93.  https://doi.org/10.1245/s10434-014-4049-z.CrossRefPubMedGoogle Scholar
  74. 74.
    Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, Lemmens VE, de Hingh IH. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134:622–8.CrossRefPubMedGoogle Scholar
  75. 75.
    Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.CrossRefPubMedGoogle Scholar
  76. 76.
    Abbasi SY, Taani HE, Saad A, Badheeb A, Addasi A. Advanced gastric cancer in jordan from 2004 to 2008: a study of epidemiology and outcomes. Gastrointest Cancer Res. 2011;4:122–7.PubMedPubMedCentralGoogle Scholar
  77. 77.
    Seshadri RA, Glehen O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol. 2016;22(3):1114–30.  https://doi.org/10.3748/wjg.v22.i3.1114.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer. 1994;73:2048–52.CrossRefPubMedGoogle Scholar
  79. 79.
    Wei G, Fang GE, Bi JW, Shen XJ, Nie MM, Xue XC, Hua JD. Efficacy of intraoperative hypotonic peritoneal chemo-hyperthermia combined with early postoperative intraperitoneal chemotherapy on gastric cancer. Ai Zheng. 2005;24:478–82.PubMedGoogle Scholar
  80. 80.
    Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer. 1999;85:529–34.CrossRefPubMedGoogle Scholar
  81. 81.
    Hirose K, Katayama K, Iida A, Yamaguchi A, Nakagawara G, Umeda S, Kusaka Y. Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis. Oncology. 1999;57:106–14.CrossRefPubMedGoogle Scholar
  82. 82.
    Yonemura Y, de Aretxabala X, Fujimura T, Fushida S, Katayama K, Bandou E, Sugiyama K, Kawamura T, Kinoshita K, Endou Y, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepato-Gastroenterology. 2001;48:1776–82.PubMedGoogle Scholar
  83. 83.
    Kim JY, Bae HS. A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP). Gastric Cancer. 2001;4:27–33.CrossRefPubMedGoogle Scholar
  84. 84.
    Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F, Elias D. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:2370–7.CrossRefPubMedGoogle Scholar
  85. 85.
    Canbay E, Mizumoto A, Ichinose M, Ishibashi H, Sako S, Hirano M, Takao N, Yonemura Y. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol. 2014;21:1147–52.CrossRefPubMedGoogle Scholar
  86. 86.
    Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol. 1992;118:547–50.CrossRefPubMedGoogle Scholar
  87. 87.
    Yan TD, Deraco M, Baratti D, Sugarbaker PH, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237–42.CrossRefPubMedGoogle Scholar
  88. 88.
    Bryan ML, Fitzgerald NC, Levine EA, Shen P, Stewart JH, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in sarcomatosis from gastrointestinal stromal tumor. Am Surg. 2014;80(9):890–5.PubMedPubMedCentralGoogle Scholar
  89. 89.
    Al-Badawi IA, Abu-Zaid A, Azzam A, AlOmar O, AlHusaini H, Amin T. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for management of recurrent/relapsed ovarian granulosa cell tumor: a single-center experience. J Obstet Gynaecol Res. 2014;40(9):2066–75.CrossRefPubMedGoogle Scholar
  90. 90.
    Hayes-Jordan A, Green HL, Lin H, Owusu-Agyemang P. Complete cytoreduction and HIPEC improves survival in desmoplastic small round cell tumor. Ann Surg Oncol. 2014;21(1):220–4.CrossRefPubMedGoogle Scholar
  91. 91.
    Salti G, Ailabouni L, Undevia S. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal sarcomatosis. Ann Surg Oncol. 2012;19(5):1410–5.CrossRefPubMedGoogle Scholar
  92. 92.
    van Oudheusden TR, Lemmens VE, Braam HJ. Peritoneal metastases from small bowel cancer: results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in The Netherlands. Surgery. 2015;157(6):1023–7.CrossRefPubMedGoogle Scholar
  93. 93.
    Goéré D, Passot G, Gelli M, Levine EA, Bartlett DL, Sugarbaker PH, Glehen O, On behalf the PSOGI; BIG-RENAPE Working Groups. Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the peritoneal surface oncology group international (PSOGI). Int J Hyperth. 2017;8:1–35.  https://doi.org/10.1080/02656736.2017.1301576.Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of Surgical OncologyKovai Medical CentreCoimbatoreIndia
  2. 2.Department of Surgical OncologyFortis Hospital BangaloreBangaloreIndia

Personalised recommendations